Kolon

Knee arthritis osteoarthritis
Biotech

Kolon’s cell-based gene therapy fails ph.3 osteoarthritis test

With a second late-stage study set to report data in October, the biotech is holding off on determining the next steps for the osteoarthritis asset.
Nick Paul Taylor Jul 20, 2026 9:25am